Literature DB >> 26315375

LC-MS/MS based determination of basal- and ACTH-stimulated plasma concentrations of 11 steroid hormones: implications for detecting heterozygote CYP21A2 mutation carriers.

A E Kulle1, F G Riepe2, J Hedderich2, W G Sippell2, J Schmitz2, L Niermeyer2, P M Holterhus2.   

Abstract

OBJECTIVE: Heterozygosity in 21-hydroxylase deficiency (21OHD) has been associated with hyperandrogenemic symptoms in children and adults. Moreover, the carrier status is mandatory for genetic counseling. We aimed at defining a hormonal parameter for carrier detection by mass spectrometry.
DESIGN: Eleven basal and ACTH-stimulated steroid hormones of heterozygous carriers of CYP21A2 mutations and control individuals were compared.
METHOD: Hormones were determined in plasma samples by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 58 carriers (35 males, 23 females, age range 6-78 years) and 44 random controls (25 males, 19 females, age range 8-58 years).
RESULTS: Heterozygotes could be identified best applying the 17-hydroxyprogesterone+21-deoxycortisol/cortisol×1000 ((17OHP+21S)/F×1000) equation 30  min after ACTH injection. An optimal cut-off value of 8.4 provided 89% sensitivity and specificity. Considering this data and a published frequency of heterozygotes of 1/50 to 1/61, the positive predictive value (PPV) of this cut-off is 12%. Of note, the negative predictive value (NPV) excluding heterozygosity in a given patient is 99.8%.
CONCLUSION: Considering only marginal biochemical effects anticipated from heterozygosity, the stimulated ((17OHP+21S)/F×1000) identifies and excludes heterozygotes remarkably well. Nevertheless, LC-MS/MS cannot replace genetic testing, since sensitivity and specificity did not reach 100%. However, due to the considerably high NPV of the optimal cut-off and to a specificity of even 100% applying a cut-off higher than 14.7, hormonal assessment of heterozygosity can be of significant aid in conditions with limited access to genetic testing, as in some health care systems. The ((17OHP+21S)/F×1000) equation can guide diagnostic considerations in the differential diagnosis of hyperandrogenism.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26315375     DOI: 10.1530/EJE-14-1084

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  A Liquid Chromatography/Tandem Mass Spectometry Profile of 16 Serum Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of Congenital Adrenal Hyperplasia.

Authors:  Jean Fiet; Yves Le Bouc; Jérôme Guéchot; Nicolas Hélin; Marie-Anne Maubert; Dominique Farabos; Antonin Lamazière
Journal:  J Endocr Soc       Date:  2017-02-10

2.  17-Hydroxyprogesterone Response to Standard Dose Synacthen Stimulation Test in CYP21A2 Heterozygous Carriers and Non-carriers in Symptomatic and Asymptomatic Groups: Meta-analyses

Authors:  Seher Polat; Yusuf Kemal Arslan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2021-11-08

3.  A Multiclassifier System to Identify and Subtype Congenital Adrenal Hyperplasia Based on Circulating Steroid Hormones.

Authors:  Lei Ye; Zhiyun Zhao; Huixia Ren; Wencui Wang; Wenzhong Zhou; Sichang Zheng; Rulai Han; Jie Zhang; Haorong Li; Zhihan Wan; Chao Tang; Shouyue Sun; Weiqing Wang; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

4.  Duplication of The SOX3 Gene in an Sry-negative 46,XX Male with Associated Congenital Anomalies of Kidneys and the Urinary Tract: Case Report and Review of the Literature.

Authors:  V Tasic; A Mitrotti; F G Riepe; A E Kulle; N Laban; M Polenakovic; D Plaseska-Karanfilska; S Sanna-Cherchi; M Kostovski; Z Gucev
Journal:  Balkan J Med Genet       Date:  2019-08-28       Impact factor: 0.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.